621 Risk of damage progression with belimumab versus oral immunosuppressant use in patients with systemic lupus erythematosus

• Yuqing Zhang,
• Hyon Choi,
• April Jorge,
• Baijun Zhou

Affiliations

Yuqing Zhang

Hyon Choi

April Jorge

1Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital

Baijun Zhou

1Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital